Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | LRRK2 | Q5S007 | 8/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | STK4 | Q13043 | 2/20 | 0.38 |
| ▸ | STK3 | Q13188 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.38 |
| ▸ | MTOR | P42345 | 2/20 | 0.38 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.38 |
| ▸ | AKT1 | P31749 | 1/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30912112 | 1.00 | KDM4E (0.44) | KDM4ELRRK2GAASTK4STK3 | |
| SCHEMBL23344653 | 0.81 | KDM4E (0.41) | KDM4ELRRK2TP53AOC3PDE10A | |
| SCHEMBL21262215 | 0.79 | KDM4E (0.54) | KDM4ELRRK2GAASTK4STK3 | |
| SCHEMBL21262656 | 0.76 | KDM4E (0.47) | KDM4ELRRK2GAAPIK3CAMTOR | |
| SCHEMBL3575815 | 0.75 | KDM4E (0.49) | KDM4ELRRK2GAASTK4STK3 | |
| SCHEMBL24611900 | 0.74 | AURKA (0.48) | KDM4ETP53PIK3CAMTOR | |
| SCHEMBL30402068 | 0.74 | AURKA (0.48) | KDM4ETP53PIK3CAMTOR | |
| SCHEMBL18394825 | 0.73 | TP53 (0.49) | KDM4EGAATP53AOC3ADORA2A | |
| SCHEMBL24612059 | 0.73 | KDM4E (0.44) | KDM4ELRRK2TP53PIK3CAAOC3 | |
| SCHEMBL28570476 | 0.73 | KDM4E (0.44) | KDM4ELRRK2STK4STK3TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3820860-B1 | PYRIDAZINE COMPOUNDS FOR INHIBITING NAV1.8 | LIEBER INST INC (US) | 2025-10-15 | — | — | EP | disclosed |
| US-11993581-B2 | Pyridazine compounds for inhibiting Nav1.8 | LIEBER INSTITUE, INC (US) | 2024-05-28 | — | — | US | disclosed |
| EP-3820860-A1 | PYRIDAZINE COMPOUNDS FOR INHIBITING NAV1.8 | Lieber Institute, Inc. (US) | 2021-05-19 | — | — | EP | disclosed |
| US-20210139456-A1 | PYRIDAZINE COMPOUNDS FOR INHIBITING NAV1.8 | LIEBER INSTITUTE, INC | 2021-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210139456-A1 | PYRIDAZINE COMPOUNDS FOR INHIBITING NAV1.8 | SCN8A, SCN5A, SCN2A | KDM4E 3022/4885LRRK2 1681/4885GAA 1517/4885 |
| US-11993581-B2 | Pyridazine compounds for inhibiting Nav1.8 | SCN8A, SCN5A, SCN2A | KDM4E 3022/4885LRRK2 1681/4885GAA 1517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.